澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - cyproterone acetate,ethinylestradiol -

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - drospirenone, quantity: 3 mg; ethinylestradiol, quantity: 20 microgram - tablet, film coated - excipient ingredients: lactose; magnesium stearate; povidone; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3350 - this medicine is indicated for use as: ? an oral contraceptive. ? treatment of moderate acne vulgaris in women who seek oral contraception. ? treatment of symptoms of premenstrual dysphoric disorder (pmdd) in women who have chosen oral contraceptives as their method of birth control. the efficacy of drospirenone 3 mg /ethinylestradiol 20 ?g for pmdd was not assessed beyond 3 cycles. drospirenone 3 mg /ethinylestradiol 20 ?g has not been evaluated for treatment of pms (premenstrual syndrome), see section 5.1 pharmacodynamic properties - clinical trials.

马耳他 - 英文 - Medicines Authority

mithra pharmaceuticals s.a rue saint-georges 5, 4000, liege, belgium - ethinylestradiol, drospirenone - film-coated tablet - ethinylestradiol 0.02 mg drospirenone 3 mg - sex hormones and modulators of the genital system

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - ethinylestradiol, quantity: 20 microgram; drospirenone, quantity: 3 mg - tablet, uncoated - excipient ingredients: magnesium stearate; titanium dioxide; lactose monohydrate; hypromellose; purified talc; microcrystalline cellulose - yvette is indicated for use as: - an oral contraceptive. - treatment of moderate acne vulgaris in women who seek oral contraception - treatment of symptoms of premenstrual dysphoric disorder (pmdd) in women who have chosen oral contraceptives as their method of birth control. the efficacy of yvette for pmdd was not assessed beyond 3 cycles. yvette has not been evaluated for treatment of pms (premenstrual syndrome), see clinical trials.

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - ethinylestradiol, quantity: 20 microgram; drospirenone, quantity: 3 mg - tablet, uncoated - excipient ingredients: magnesium stearate; titanium dioxide; lactose monohydrate; hypromellose; purified talc; microcrystalline cellulose - leah is indicated for use as: - an oral contraceptive. - treatment of moderate acne vulgaris in women who seek oral contraception - treatment of symptoms of premenstrual dysphoric disorder (pmdd) in women who have chosen oral contraceptives as their method of birth control. the efficacy of leah for pmdd was not assessed beyond 3 cycles. leah has not been evaluated for treatment of pms (premenstrual syndrome), see clinical trials.

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - ethinylestradiol, quantity: 0.03 mg; drospirenone, quantity: 3 mg - tablet, film coated - excipient ingredients: hypromellose; magnesium stearate; purified talc; lactose monohydrate; titanium dioxide; microcrystalline cellulose - for use as an oral contraceptive.

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - ethinylestradiol, quantity: 30 microgram; drospirenone, quantity: 3 mg - tablet, film coated - excipient ingredients: lactose; povidone; magnesium stearate; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3350 - indicated for use as an oral contraceptive

比利时 - 英文 - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

laboratorios león farma s.a. - ethinylestradiol 3,474 mg; etonogestrel 11 mg - vaginal delivery system - 0,120 mg/24 h - 0,015 mg/24 h - etonogestrel 11 mg; ethinylestradiol 3.474 mg - vaginal ring with progestogen and estrogen

坦桑尼亚 - 英文 - Tanzania Medicinces & Medical Devices Authority

bayer east africa limited, kenya - levonorgestrel , ethinylestradiol - film coated tablet - ethinylestradiol 30 Μcg + levonorgestrel 150 Μcg

澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

lupin australia pty limited - drospirenone, quantity: 3 mg; ethinylestradiol, quantity: 20 microgram - tablet, film coated - excipient ingredients: pregelatinised maize starch; lactose monohydrate; magnesium stearate; maize starch; titanium dioxide; hypromellose; macrogol 400 - ethinylestradiol/ drospirenone tablet is indicated for use as:,?an oral contraceptive.,?treatment of symptoms of premenstrual dysphoric disorder (pmdd) in women who have chosen oral contraceptives as their method of birth control. the efficacy of ethinylestradiol/ drospirenone tablet for pmdd was not assessed beyond 3 cycles. ethinylestradiol/ drospirenone tablet has not been evaluated for treatment of pms (premenstrual syndrome).